Short answer
Embecta Corp. (EMBC) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $272M (down 8.1% year over year) with net income of $21M.
Q2 2026 key financials · XBRL
- Revenue
- $272M
- −8.1% YoY · +22.5% QoQ
- Net income
- $21M
- −53.6% YoY · +614.6% QoQ
- Operating margin
- 17.9%
- Gross margin
- 56.4%
- EPS (diluted)
- $0.36
- −53.8% YoY · +614.3% QoQ
Source: XBRL data from the Embecta Corp. (EMBC) Q2 2026 10-Q on SEC EDGAR. USD.
Embecta Corp. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $271.7M, down 8.1% YoY from $295.5M, driven by $20.1M price and $19.9M volume declines
- Gross margin 56.4% vs 66.7% YoY; operating income $48.7M vs $94.0M
- Owen Mumford contributed $13.8M revenue, partially offsetting legacy portfolio declines
- Owen Mumford acquisition for $169.9M upfront cash; $8.7M stock repurchases and dividend reduced to $0.01 per share
- Headwinds from tariffs, supply-chain costs, pricing pressure, and emerging diabetes therapies reducing injection-device demand
Risk Factors
- No material risk-factor changes from the 2025 Form 10-K or March 31, 2026 Form 10-Q
- Revolving commitments reduced from $500 million to $310 million under the August 6, 2026 credit amendment
- $100 million revolving tranche matures March 31, 2027, creating near-term refinancing exposure
- Extended tranche interest spread increased to Term SOFR plus 3.50% from 3.00%
- More restrictive covenants may constrain growth investment and competitive execution
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Embecta Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.